PURPOSE: Acyclic retinoid (ACR) has been shown to be a promising chemopreventive agent for hepatocellular carcinoma (HCC) after curative resection. The effects of retinoid are mediated by retinol-binding proteins (RBPs) through regulating cell proliferation and differentiation. PATIENTS AND METHODS: This study investigated the clinical significance of RBP5 in HCC. RBP5 mRNA level was examined by real-time quantitative PCR on 52 matched tumor and adjacent non-tumor liver tissues, and on ten normal livers. Expression of RBP5 protein was examined using Western blotting analysis and immunohistochemistry. RESULTS: Down-regulation of RBP5 was found in HCC tissues at both mRNA and protein levels. Decreased RBP5 level was closely related to poor differentiation (P=0.02) and large tumor size (P=0.01). Low level of RPB5 was associated with poor overall survival (P=0.02), and was an independent prognostic factor for HCC. CONCLUSIONS: Our study revealed that RBP5 down-regulation in HCC was associated with aggressive tumor features, suggesting an important role of RPB5 in HCC progression.
PURPOSE: Acyclic retinoid (ACR) has been shown to be a promising chemopreventive agent for hepatocellular carcinoma (HCC) after curative resection. The effects of retinoid are mediated by retinol-binding proteins (RBPs) through regulating cell proliferation and differentiation. PATIENTS AND METHODS: This study investigated the clinical significance of RBP5 in HCC. RBP5 mRNA level was examined by real-time quantitative PCR on 52 matched tumor and adjacent non-tumor liver tissues, and on ten normal livers. Expression of RBP5 protein was examined using Western blotting analysis and immunohistochemistry. RESULTS: Down-regulation of RBP5 was found in HCC tissues at both mRNA and protein levels. Decreased RBP5 level was closely related to poor differentiation (P=0.02) and large tumor size (P=0.01). Low level of RPB5 was associated with poor overall survival (P=0.02), and was an independent prognostic factor for HCC. CONCLUSIONS: Our study revealed that RBP5 down-regulation in HCC was associated with aggressive tumor features, suggesting an important role of RPB5 in HCC progression.
Authors: Siu Tim Cheung; San Yu Wong; Ka Ling Leung; Xin Chen; Samuel So; Irene O Ng; Sheung Tat Fan Journal: Clin Cancer Res Date: 2004-11-15 Impact factor: 12.531
Authors: Siu Tim Cheung; Jenny C Y Ho; Ka Ling Leung; Xin Chen; Daniel Y T Fong; Samuel So; Sheung Tat Fan Journal: Neoplasia Date: 2005-02 Impact factor: 5.715
Authors: W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters Journal: N Engl J Med Date: 1990-09-20 Impact factor: 91.245
Authors: Eduardo F Farias; David E Ong; Norbert B Ghyselinck; Shigeo Nakajo; Yuvarani S Kuppumbatti; Rafael Mira y Lopez Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: David Roberts; Stephen J Williams; Dusica Cvetkovic; Jillian K Weinstein; Andrew K Godwin; Steven W Johnson; Thomas C Hamilton Journal: DNA Cell Biol Date: 2002-01 Impact factor: 3.311
Authors: Masumi Suzui; Muneyuki Masuda; Jin T E Lim; Chris Albanese; Richard G Pestell; I Bernard Weinstein Journal: Cancer Res Date: 2002-07-15 Impact factor: 12.701
Authors: Danni A Gadd; Robert F Hillary; Daniel L McCartney; Liu Shi; Aleks Stolicyn; Neil A Robertson; Rosie M Walker; Robert I McGeachan; Archie Campbell; Shen Xueyi; Miruna C Barbu; Claire Green; Stewart W Morris; Mathew A Harris; Ellen V Backhouse; Joanna M Wardlaw; J Douglas Steele; Diego A Oyarzún; Graciela Muniz-Terrera; Craig Ritchie; Alejo Nevado-Holgado; Tamir Chandra; Caroline Hayward; Kathryn L Evans; David J Porteous; Simon R Cox; Heather C Whalley; Andrew M McIntosh; Riccardo E Marioni Journal: Nat Commun Date: 2022-08-09 Impact factor: 17.694